Literature DB >> 31183524

Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry.

Truls E Bjerklund Johansen1,2,3, Per-Henrik Zahl4, Eduard Baco5, Riccardo Bartoletti6, Gernot Bonkat7, Franck Bruyere8,9, Tommaso Cai10, Mete Cek11, Ekaterina Kulchavenya12, Bela Köves13, Vladimir Mouraviev14,15, Adrian Pilatz16, Zafer Tandogdu5,17, Peter Tenke13, Florian M E Wagenlehner16.   

Abstract

BACKGROUND: A 68-year-old man died of cerebral arterial embolism 6 days after transrectal prostate biopsy with a single p.o. dose of trimethoprim sulfamethoxazole (TMP-SMX) as prophylaxis. The case precipitated analysis of local antibiotic resistance and complication rates.
MATERIALS AND METHODS: Data on E. coli resistance from Oslo University Hospital and national data on hospitalizations and mortality after biopsy were retrieved from local microbiology files and the Norwegian Patient Registry (NPR) 2011-2017.
RESULTS: Urine E. coli resistance against TMP-SMX increased from 35% in 2013 to more than 60% in 2015. For ciprofloxacin, the resistance increased from 15% in 2013 to about 45% in 2016. The highest annual E. coli resistance in blood cultures for TMP-SMX and ciprofloxacin was 37% and 28%, respectively. 10% of patients were hospitalized with a diagnosis of infection within the first 60 days after biopsy and there was a relative increase in mortality rate of 261% within the first 30 days. Due to the severity of the figures, the story and the NPR data were published in Norway's leading newspaper and were succeeded by a series of chronicles and commentaries.
CONCLUSIONS: Several critical points of the biopsy procedure were not performed according to current standards. We believe that the patient might have died of septic embolism after biopsy. As a result of the findings and the debate, local practice was changed from transrectal to transperineal prostate biopsies.

Entities:  

Keywords:  Antibiotic resistance; Complications; Death; Hospitalization; Prostate biopsy

Mesh:

Substances:

Year:  2019        PMID: 31183524     DOI: 10.1007/s00345-019-02837-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  12 in total

1.  Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution.

Authors:  Matthew J Roberts; Alastair Macdonald; Sachinka Ranasinghe; Harrison Bennett; Patrick E Teloken; Patrick Harris; David Paterson; Geoff Coughlin; Nigel Dunglison; Rachel Esler; Robert A Gardiner; Thomas Elliott; Louisa Gordon; John Yaxley
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-05       Impact factor: 5.554

2.  Urogenital infections.

Authors:  Florian Wagenlehner
Journal:  World J Urol       Date:  2020-01       Impact factor: 4.226

3.  Transrectal ultrasound-guided prostate needle biopsy remains a safe method in confirming a prostate cancer diagnosis: a multicentre Australian analysis of infection rates.

Authors:  Cameron J Parkin; Daniel Gilbourd; Richard Grills; Sue Chapman; Sydney Weinstein; Neil Joshi; Balasubramaniam Indrajit; Jonathan Kam; Teresa Smilovic; Andrew Shepherd; Njeri Gikenye; Mark W Louie-Johnsun
Journal:  World J Urol       Date:  2021-10-21       Impact factor: 4.226

Review 4.  Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study).

Authors:  Badar M Mian; Ronald P Kaufman; Hugh A G Fisher
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-25       Impact factor: 5.554

5.  Multicentre clinical evaluation of the safety and performance of a simple transperineal access system for prostate biopsies for suspected prostate cancer: The CAMbridge PROstate Biopsy DevicE (CamPROBE) study.

Authors:  Vincent J Gnanapragasam; Kelly Leonard; Michal Sut; Cristian Ilie; Jonathan Ord; Jacques Roux; Maria Consuelo Hart Prieto; Anne Warren; Priya Tamer
Journal:  J Clin Urol       Date:  2020-06-12

6.  The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis.

Authors:  Katarzyna Piekarska; Katarzyna Zacharczuk; Tomasz Wołkowicz; Mateusz Mokrzyś; Natalia Wolaniuk; Magdalena Nowakowska; Stanisław Szempliński; Jakub Dobruch; Rafał Gierczyński
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-07       Impact factor: 3.944

7.  Safety and feasibility of freehand transperineal prostate biopsy under local anesthesia: Our initial experience.

Authors:  Ananthakrishnan Sivaraman; Vasantharaja Ramasamy; P Aarthy; Vinoth Sankar; P B Sivaraman
Journal:  Indian J Urol       Date:  2022-01-01

Review 8.  Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis.

Authors:  Spyridon P Basourakos; Mark N Alshak; Patrick J Lewicki; Emily Cheng; Michael Tzeng; Antonio P DeRosa; Mathew J Allaway; Ashley E Ross; Edward M Schaeffer; Hiten D Patel; Jim C Hu; Michael A Gorin
Journal:  Eur Urol Open Sci       Date:  2022-01-29

9.  Is antibiotic prophylaxis still mandatory for transperineal prostate biopsy? Results of a comparative study.

Authors:  Giacomo M Pirola; Marilena Gubbiotti; Emanuele Rubilotta; Daniele Castellani; Nicolò Trabacchin; Alessandro Tafuri; Alessandro Princiotta; Eugenio Martorana; Filippo Annino; Alessandro Antonelli
Journal:  Prostate Int       Date:  2021-12-07

10.  Comparison of Fluoroquinolones and Other Antibiotic Prophylaxis Regimens for Preventing Complications in Patients Undergoing Transrectal Prostate Biopsy.

Authors:  Gabriele Tulone; Sofia Giannone; Piero Mannone; Alessio Tognarelli; Tommaso Di Vico; Rosa Giaimo; Alessandro Zucchi; Marta Rossanese; Alberto Abrate; Nicola Pavan; Francesco Claps; Vincenzo Ficarra; Riccardo Bartoletti; Alchiede Simonato
Journal:  Antibiotics (Basel)       Date:  2022-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.